Clinical trials: Degenerative; Dementia
Dementia, Alzheimer Disease
The Healthy Patterns Sleep Study
The Healthy Patterns Study intervention is a home-based activity intervention designed to improve symptoms of circadian rhythm disorders (CRD) and quality of life (QOL) in home-dwelling persons with dementia.
- Conditions
- Dementia, Alzheimer Disease, Circadian Rhythm Disorders, Circadian Rhythm Sleep Disorder
- Trial name
- NCT03682185
- Testing
- Attention-Control Condition, Timed Activity Intervention
- Where
- United States
- Volunteers
- 421 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Alzheimer's Disease
Biodistribution of 11C-PIB PET in Alzheimer's Disease, Frontotemporal Dementia, and Cognitively Normal Elderly
Alzheimer's disease (AD) is characterized by neuritic plaques, neurofibrillary tangles, and neuronal cell loss. Amyloid plaques are believed to play an integral role in AD.
- Trial name
- 11C-PIB PET (NCT00811122)
- Testing
- 11C-PIB PET Scan, FDG-PET Scan
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- University of Utah
Alzheimer Disease
Ectosomes, New Biomarkers of Tau Pathology?
In Alzheimer's disease (AD), neurofibrillary degeneration (NFD) is characterized by the intraneuronal aggregation of Tau proteins.
- Trial name
- ECTAUSOME (NCT03381482)
- Testing
- CSF drawing during spinal anaesthesia, Fasting blood sample, Lumbar puncture
- Where
- France
- Volunteers
- 71 people
- Sponsor
- University Hospital, Lille
Amyotrophic Lateral Sclerosis, Frontotemporal Lobar Degeneration
Natural History and Biomarkers of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Caused by the C9ORF72 Gene Mutation
Background: Some people have a mutation in the C9ORF72 gene that causes amyotrophic lateral sclerosis (ALS) or frontotemporal dementia (FTD). The mutation causes a small piece of DNA to repeat itself thousands of times.
- Trial name
- NCT01925196
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Alzheimer Disease
PET Study With 11 C-PIB to Evaluate Amyloid Protein Deposits in Mild Cognitive Disorder, Alzheimer's Disease and Early Frontotemporal Degeneration.
Preclinical and clinical data have demonstrated the ability of the 11C-PIB tracer to selectively bind accumulations of amyloid protein, a neuropathological marker characteristic of the neurodegenerative pathologies covered by…
- Trial name
- NCT06179979
- Testing
- PET/CT with 11C-PiB
- Volunteers
- 60 people
- Sponsor
- IRCCS San Raffaele
Healthy Volunteers, Tauopathies
A First-in-Human Study to Assess Single Doses of APNmAb005 in Healthy Participants
This is a Phase 1, first-in-human (FIH), double-blinded, placebo-controlled study where healthy subjects are randomly allocated to receive APNmAb005 or placebo.
- Conditions
- Healthy Volunteers, Tauopathies, Alzheimer Disease
- Trial name
- NCT05344989
- Testing
- APNmAb005
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- APRINOIA Therapeutics, LLC
Alzheimer Disease, Mild Cognitive Impairment
Longitudinal Cognitive Assessment by BoCA
The Boston Cognitive Assessment (BoCA) is a self-administered online test intended for longitudinal cognitive monitoring. BoCA uses random not-repeating tasks to minimize learning effects.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Vascular Dementia, Frontotemporal Dementia
- Trial name
- BoCA (NCT04114994)
- Testing
- Boston Cognitive Assessment (BoCA)
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Alzheimer's Light LLC
Alzheimer Disease
Study of Tau Imaging With the Use of [18F]MK-6240 Tracer
The recent development of a PET tracer,[18F]MK-6240(an[18F]tau imaging agent,CerveauTechnologies)that has high affinity for the human phosphorylated tau deposits in AD brain offers new opportunities to investigate tau pathology.
- Trial name
- MKADAD (NCT04104659)
- Testing
- MK 6240
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Tammie L. S. Benzinger, MD, PhD
Dementia, Alzheimer Disease
Improving Prognostic Confidence in Neurodegenerative Diseases Causing Dementia Using Peripheral Biomarkers and Integrative Modeling
To develop a model to predict disease progression in a large cohort of patients across a variety of neurodegenerative diseases, including Mild Cognitive Impairment (MCI) and dementia due to any neurodegenerative disease…
- Conditions
- Dementia, Alzheimer Disease, Dementia With Lewy Bodies, Vascular Dementia
- Trial name
- CRND TorCA (NCT06529744)
- Where
- 4 sites in Canada
- Volunteers
- 500 people
- Sponsor
- University Health Network, Toronto
Parkinson Disease, Dementia With Lewy Bodies
Optimization of Morphomer-based Alpha-synuclein PET Tracers
The aim of the project is to develop the first alpha-synuclein (a-syn)-specific PET tracer. The research phase will exploit ACI's proprietary MorphomerTM library and extensively optimized screening workflow.
- Conditions
- Parkinson Disease, Dementia With Lewy Bodies, Multiple System Atrophy, Corticobasal Degeneration
- Trial name
- NCT05067192
- Where
- Sweden
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Skane University Hospital
Progressive Supranuclear Palsy, Corticobasal Degeneration
4 Repeat Tauopathy Neuroimaging Initiative
The purpose of this study is to evaluate several different tests, including brain imaging, eye movement testing, body fluid samples, measurements of memory and other thinking abilities, and measures of functional independence in…
- Trial name
- 4RTNI (NCT01804452)
- Testing
- Observational Study
- Where
- 2 sites in United States
- Volunteers
- 110 people
- Sponsor
- University of California, San Francisco
Amyotrophic Lateral Sclerosis, Frontotemporal Dementia
TRIAL READY (Clinical Trial Readiness)
This study, being conducted under the auspice of the CReATe Consortium, will enroll patients with ALS and related disorders as well as healthy controls, with the goal of facilitating clinical validation of leading…
- Conditions
- Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, ALS-Frontotemporal Dementia, Primary Lateral Sclerosis
- Trial name
- NCT03912987
- Where
- 3 sites in United States
- Volunteers
- 610 people, healthy volunteers welcome
- Sponsor
- University of Miami
ALS, Amyotrophic Lateral Sclerosis
NYSCF Scientific Discovery Biobank
The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate diverse disease research using cells from the body (such as skin or blood cells) to make stem cells and other types of cells…
- Conditions
- ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset
- Trial name
- NCT06203106
- Testing
- Biological Sample Collection
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- New York Stem Cell Foundation Research Institute
Amnestic Mild Cognitive Impairment - aMCI, AD-MCI
Temporal Interference Stimulation Treatment in Patients With Cognitive Impairment
This study aims to evaluate the efficacy and safety of temporal interference stimulation (TIS), a non-invasive neuromodulation technique, in improving cognitive function in patients with cognitive impairment.
- Conditions
- Amnestic Mild Cognitive Impairment - aMCI, AD-MCI, AD - Alzheimer's Disease, FTD
- Trial name
- TIS (NCT07643363)
- Testing
- Temporal Interference Stimulation, Targeted Cognitive Training, General Cognitive Training
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tianjin Huanhu Hospital
Primary Progressive Nonfluent Aphasia
Transcranial Magnetic Stimulation in Nonfluent/Agrammatic Variant Primary Progressive Aphasia
Nonfluent/agrammatic variant primary progressive aphasia (nf/avPPA) is a fatal neurodegenerative disease that begins with isolated language deficits. There is currently no cure or treatment for this disease.
- Trial name
- NCT03153540
- Testing
- Active iTBS
- Where
- Canada
- Volunteers
- 2 people
- Sponsor
- University of British Columbia
Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 3
A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD
The goal of this first-in-human clinical trial is to assess the safety and tolerability of four doses of a new study drug called VO659 in people with genetic disorders called spinocerebellar ataxia type 1, type 3 or Huntington's…
- Conditions
- Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 3, Huntington Disease
- Trial name
- NCT05822908
- Testing
- VO659
- Where
- 14 sites in Denmark, France and 4 more
- Volunteers
- 68 people
- Sponsor
- Vico Therapeutics B. V.
Frontotemporal Dementia, Frontotemporal Degeneration
Voices Of Individuals: Challenges and Experiences Of bvFTD
The VOICE Of bvFTD study is a telephone interview research study about life with or at risk for behavioral variant frontotemporal dementia (bvFTD).
- Conditions
- Frontotemporal Dementia, Frontotemporal Degeneration, Frontotemporal Dementia, Behavioral Variant, FTD
- Trial name
- NCT04060082
- Testing
- Telephone Interview
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- University of Pennsylvania
Parkinson Disease, Parkinsonism
Misfolded Proteins in the Skin of People With Parkinson's Disease and Other Parkinsonism
The purpose of this study is to determine whether identification of misfolded proteins in the skin will help to determine what sort of parkinsonism someone has.
- Conditions
- Parkinson Disease, Parkinsonism, Dementia With Lewy Bodies, Multiple System Atrophy
- Trial name
- NCT04518059
- Testing
- punch skin biopsy
- Where
- 2 sites in United States
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- University Hospitals Cleveland Medical Center
Down Syndrome, Alzheimer's Disease
Down Syndrome Biomarker Initiative (DSBI)
Non-randomized natural history study involving 12 subjects with Down Syndrome, who are aged 30-60 years old. This study will observe 3 different groups: four non-demented subjects between ages 30-40 years old, four non-demented…
- Trial name
- DSBI (NCT02141971)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Michael Rafii
Progressive Supranuclear Palsy (PSP), Healthy Participants
First-in-Human Study for the Safety and Evaluation of Two 4R Tau Ligands as Potential PET Radioligands for Imaging Tau Protein in the Brain
This clinical study is being conducted to learn more about two new imaging drugs, called [18F]ABBV-964i and [18F]ABBV-965i, which are designed to help doctors see changes in the brain related to a condition called Progressive…
- Trial name
- NCT07348276
- Testing
- [18F]ABBV-964i, [18F]ABBV-965i, Lead Candidate
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Invicro